Trial Profile

Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]), Temozolomide, and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vorinostat (Primary) ; Temozolomide
Indications Astrocytoma; Glioblastoma; Gliosarcoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

03 Aug 2022 Status changed from active, no longer recruiting to completed.
07 Jun 2016 Results assessing RNAseq-signatures (n=76) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
03 Jun 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com